Who are LeonaBio, Inc.'s main suppliers?

LeonaBio, Inc. (LONA) key suppliers include: SERMONIX, SERMONIX-PHARMACEUTICALS-INC, SHANGHAI-HENLIUS-BIOTECH-INC, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated and 1 more. View the full supplier network at chainsifter.com/chain/LONA.

Who are LeonaBio, Inc.'s major customers?

LeonaBio, Inc. (LONA) key customers include: Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, DELAWARE-GENERAL-CORPORATION, SERMONIX-PHARMACEUTICALS-INC, WASHINGTON-BUSINESS-CORPORATION. View the full customer network at chainsifter.com/chain/LONA.

What sector is LeonaBio, Inc. in?

LeonaBio, Inc. (LONA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

LeonaBio, Inc. Suppliers, Customers & Supply Chain (LONA)

6Suppliers

5Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

LeonaBio, Inc. (LONA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

5Distinct source URLs

10High confidence

0.798Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LeonaBio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
SERMONIX	SERMONIX	92%	As consideration for the rights granted to the Company under the Sermonix License Agreement entered into between the Company and Sermonix on December 18, 2025, the Company issued to Sermonix the Serm…
SERMONIX-PHARMACEUTICALS-INC	SERMONIX-PHARMACEUTICALS-INC	90%	Sermonix disclosed to the Company that it incurred aggregate cash expenditures in conducting the ELAINE-3 Study of approximately $14 million, $12 million and $5 million in each of 2023, 2024 and 2025…
SHANGHAI-HENLIUS-BIOTECH-INC	SHANGHAI-HENLIUS-BIOTECH-INC	85%	the Company is coordinating with Sermonix and Shanghai Henlius Biotech, Inc. (“ Henlius ”), Sermonix’s exclusive licensee for oral lasofoxifene in Asia and certain countries in the Middle East
LGND	Ligand Pharmaceuticals Incorporated	80%	Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: granting the Company exclusive licenses and rights to develop, manufacture and commercialize oral forms of the select…
LGND	Ligand Pharmaceuticals Incorporated	80%	granting the Company exclusive licenses and rights to develop, manufacture and commercialize oral forms of the selective estrogen-receptor modulator known as lasofoxifene
LIGAND	LIGAND	80%	we entered into a direct license agreement with Ligand (the "Ligand Agreement") to replace Sermonix's license from Ligand

LeonaBio, Inc. Customers

Ticker	Name	Confidence	Evidence
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: an adequate number of suitable pati…
LGND	Ligand Pharmaceuticals Incorporated	72%	an adequate number of suitable patients to participate in a clinical trial on a timely basis; • the number of patients required for clinical trials of our drug candidates may be larger than we antici…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	alties that could adversely affect our business, financial condition or operating results or result in harm to our reputation and brand, sanctions, consent decrees, injunctions or other remedies requ…
SERMONIX-PHARMACEUTICALS-INC	SERMONIX-PHARMACEUTICALS-INC	62%	an adequate number of suitable patients to participate in a clinical trial on a timely basis; • the number of patients required for clinical trials of our drug candidates may be larger than we antici…
WASHINGTON-BUSINESS-CORPORATION	WASHINGTON-BUSINESS-CORPORATION	62%	failures or breaches of our systems or those used by our CROs or other contractors or consultants. We are dependent upon our own or third-party information technology systems, infrastructure and data…

LeonaBio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LONA-DEBT	Debt stack $691,000	90%	Market cache reports total debt of $691,000.
LONA-DEBT-10762	Warrants outstanding: 4579000	90%	xbrl warrant detail from xbrl 2025-12-31.
LONA-DEBT-10763	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.

LeonaBio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LeonaBio, Inc..

LeonaBio, Inc. Ownership

Holder	Name	Confidence	Evidence
LONA-OWNER-PERCEPTIVE-ADVISORS-LLC	PERCEPTIVE ADVISORS LLC	90%	13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 40 tracked holders.

LeonaBio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
PLX	Protalix BioTherapeutics, Inc.	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	1	['customer', 'supplier']
CRMD	CorMedix Inc.	100.00	2
AGEN	Agenus Inc.	100.00	2
ELUT	Elutia Inc.	100.00	2
SGMO	Sangamo Therapeutics, Inc.	100.00	2
VKTX	Viking Therapeutics, Inc.	100.00	2
OBIO	Orchestra BioMed Holdings, Inc.	100.00	2
OVID	Ovid Therapeutics Inc.	100.00	2
DNTH	Dianthus Therapeutics, Inc.	50.00	2
XOMA	XOMA Royalty Corporation	50.00	2
CURX	Curanex Pharmaceuticals Inc	50.00	2
BSX	Boston Scientific Corporation	50.00	2
PTHS	Pelthos Therapeutics Inc.	50.00	2
ANEB	Anebulo Pharmaceuticals, Inc.	50.00	2
XOMAP	XOMA Royalty Corporation	50.00	2
OABIW	OmniAb, Inc.	50.00	2
RYLAZE	RYLAZE	23.09	2
LLY	Eli Lilly and Company	14.78	2
PVLA	Palvella Therapeutics, Inc.	14.78	2

LeonaBio, Inc. Supply Chain